Market revenue in 2023 | USD 81.4 million |
Market revenue in 2030 | USD 108.8 million |
Growth rate | 4.2% (CAGR from 2023 to 2030) |
Largest segment | Outpatient facilities |
Fastest growing segment | Home Care |
Historical data | 2018 - 2022 |
Base year | 2023 |
Forecast period | 2024 - 2030 |
Quantitative units | Revenue in USD million |
Market segmentation | Hospitals, Outpatient Facilities, Home Care, Research & Manufacturing |
Key market players worldwide | Thermo Fisher Scientific Inc, Qiagen NV, Illumina Inc, Roche Holding AG ADR, BD, Agilent Technologies Inc, Myriad Genetics Inc, Koninklijke Philips NV, Abbott Laboratories, Hitachi Ltd, Danaher Corp, Prestige Medical |
No credit card required*
Name | Profile | # Employees | HQ | Website |
---|
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to pancreatic cancer diagnostic market will help companies and investors design strategic landscapes.
Outpatient facilities was the largest segment with a revenue share of 64% in 2023. Horizon Databook has segmented the France pancreatic cancer diagnostic market based on hospitals, outpatient facilities, home care, research & manufacturing covering the revenue growth of each sub-segment from 2018 to 2030.
France’s market is projected to grow at a lucrative rate during the forecast period, due to high cancer prevalence, the increasing burden of chronic diseases on the healthcare industry, and the growing number of initiatives adopted by key players.
For instance, in February 2024, Ipsen’s Onivyde regimen, comprising irinotecan liposome injection with oxaliplatin, fluorouracil, and leucovorin (NALIRIFOX), was FDA-approved as a first-line therapy for metastatic PDAC (mPDAC).
This approval follows positive Phase III NAPOLI 3 trial results demonstrating significant improvements in overall survival and progression-free survival compared to current standard therapies. Onivyde is now recognized as a potential new standard-of-care treatment, addressing an unmet need in cancer with a poor prognosis and limited treatment options.
Horizon Databook provides a detailed overview of country-level data and insights on the France pancreatic cancer diagnostic market , including forecasts for subscribers. This country databook contains high-level insights into France pancreatic cancer diagnostic market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account